ResearcherZhengzhou UniversityActive in the last 2 years
Qingke Duan
Matched on ORCID iD 0000-0002-8840-8830; OpenAlex author ID A5102297691. Sources: OpenAlex.
Their work
- Papers
- 8 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 11
2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 3 papers · 2020: none · 2021: none · 2022: none · 2023: 1 paper · 2024: none · 2025: none · 2026: 1 paper
Papers 8
- Interaction between m6A and YAP1 mechanotransduction pathways is essential for mechanical memory and matrix remodeling in pancreatic cancer. Co-author DOI 10.7150/ijbs.125330↗
- Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreati… Co-author DOI 10.1186/s13578-023-01155-8↗
- ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. Co-author DOI 10.1016/j.omto.2019.07.005↗
- High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. Co-author DOI 10.1186/s13046-019-1209-9↗
- Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentiate the motility of pancreatic cancer cel… Co-author DOI 10.1186/s13578-019-0312-0↗
- Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. First author DOI 10.1111/jcmm.13126↗
- Gemcitabine treatment promotes pancreatic cancer stemness through the Nox/ROS/NF-κB/STAT3 signaling cascade. First author DOI 10.1016/j.canlet.2016.08.023↗
- Bmi1 inhibition enhances the sensitivity of pancreatic cancer cells to gemcitabine. Co-author DOI 10.18632/oncotarget.9293↗
Closest collaborators
The 11 strongest of 11 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Tao Yin · 7 shared papers, 2016–2023 · strength 0.67
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Chunyou Wang · 7 shared papers, 2016–2023 · strength 0.67
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Zhengle Zhang · 6 shared papers, 2016–2023 · strength 0.58
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentia… DOI 10.1186/s13578-019-0312-0↗
- Hehe Li · 5 shared papers, 2017–2023 · strength 0.55
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Heshui Wu · 5 shared papers, 2016–2023 · strength 0.51
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Paper Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentially potentia… DOI 10.1186/s13578-019-0312-0↗
- Shihong Wu · 4 shared papers, 2019–2023 · strength 0.48
- Paper Correction: Combination chemotherapy of valproic acid (VPA) and gemcitabine regulates STAT3/Bmi1 pathway to differentia… DOI 10.1186/s13578-023-01155-8↗
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Hengqiang Zhao · 5 shared papers, 2016–2019 · strength 0.39
- Paper ROS/KRAS/AMPK Signaling Contributes to Gemcitabine-Induced Stem-like Cell Properties in Pancreatic Cancer. DOI 10.1016/j.omto.2019.07.005↗
- Paper High glucose promotes pancreatic cancer cells to escape from immune surveillance via AMPK-Bmi1-GATA2-MICA/B pathway. DOI 10.1186/s13046-019-1209-9↗
- Paper Up-regulation of glycolysis promotes the stemness and EMT phenotypes in gemcitabine-resistant pancreatic cancer cells. DOI 10.1111/jcmm.13126↗
- Jiaoshun Chen · 1 shared paper, 2026 · strength 0.32
- Tao Yin · 1 shared paper, 2026 · strength 0.32
- Tao Liu · 1 shared paper, 2016 · strength 0.06
- Pengfei Shi · 1 shared paper, 2016 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.